<DOC>
	<DOCNO>NCT02734238</DOCNO>
	<brief_summary>The objective study determine whether maintain eugonadal state , severe , sustain energy deficit , attenuate physiological decrement , particularly loss lean body mass , maintain mental performance .</brief_summary>
	<brief_title>Physiological Psychological Effects Testosterone During Severe Energy Deficit Recovery</brief_title>
	<detailed_description>This study enroll 60 physically active men 3-phase randomize , placebo-controlled trial . After complete 14-day ( free-living , phase 1 ) , energy-adequate , diet-acclimation phase ( protein , 1.6 g∙kg-1∙d-1 ; fat 30 % total energy intake , remain energy derive carbohydrate ) , participant randomize one two experimental group undergo 28-day ( live-in , phase 2 ) , 55 % energy deficit phase : energy deficit alone ( DEF ) energy deficit + exogenous testosterone ( DEF+TEST ) . Recovery ( free-living , phase 3 ) assess complete phase 2 determine body mass recover within ± 2.5 % initial body mass ( duration vary , 42-day maximum phase 3 ) . This study delineate contribution testosterone decline physical mental demand encounter Warfighters military training combat operation complex marker physiological psychological status , address direct , consistently observe , gap knowledge .</detailed_description>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Physically active ( least 2 day per week aerobic and/or resistance exercise ) Not take prescription medication and/or willing refrain medication use prior throughout entire study period , unless provided/approved study physician Willing refrain alcohol , smoking , ecigarettes , use nicotine product , caffeine , dietary supplement use throughout entire study period At discretion study physician , washout period medication , supplement , overthecounter medication ≥ 1 4 week Washout period caffeine alcohol ≥ 7 day Willing live Pennington Biomedical Research Center inpatient unit 28 consecutive day Willing urine drug screen Meets agespecific U.S. Army body composition standard accord Army Regulation 6009 , include estimate percent body fat base height , weight , circumference measure ( neck waist ) Total testosterone concentration within normal physiological range , total testosterone ( 3001,000 ng/dL ) . Musculoskeletal injury compromise exercise capability Diagnosed cardiometabolic disorder ( i.e. , hypertension , hyperlipidemia , kidney disease , diabetes , etc . ) Allergies intolerance food , vegetarian practice , history complication lidocaine Anabolic steroid , human growth hormone , nutritional testosterone precursorlike supplement use within past 6 month Will refrain smoking ( nicotine product ) , alcohol , caffeine , dietary supplement study Any use antibiotic , except topical antibiotic , within 3 month study participation Colonoscopy within 3 month study participation Chronic use laxative , stool softener , antacid , antidiarrheal medication ( ≥ week ) History gastrointestinal disease ( e.g. , celiac , irritable bowel syndrome , colitis , Crohn 's disease ) Restrained eater ( ThreeFactor Eating Questionnaire ) assess study 's psychological behavioral assessment staff Adults unable consent Women Prisoners Metal implant , claustrophobia , head size incompatible MRI equipment , etc . Sedentary engage &lt; 2 day physical activity per week ( aerobic and/or resistance training ) Exceeds agespecific U.S. Army body composition standard accord Army Regulation 6009 Previous history kidney stone unless otherwise approve medical investigator Systolic blood pressure &gt; 150 diastolic blood pressure &gt; 95 mmHg Previous history breast prostate cancer Previous history Chronic Obstructive Pulmonary Disease Obstructive Sleep Apnea Findings lab result prostatespecific antigen &gt; 3ng/ml , Hematocrit &gt; 50 % , positive urine drug screen Based investigative team 's clinical judgment , subject may appropriate participation study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>